Page 170 - Genentech News Today

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of glofitamab for fixed-duration use in adult patients with relapsed or refractory diffuse large B-cell lymphoma following 2 or more lines of systemic therapy.

Stanford President Marc Tessier-Lavigne has declined to answer dozens of questions and made statements about his research that contradict accounts of fellow researchers, Genentech and the scientific record. Meanwhile, professors have publicly questioned his ability to lead as he grapples with mounting allegations.

/PRNewswire/ -- DelveInsights FAK Inhibitors Competitive Landscape report delivers an in-depth understanding of the FAK inhibitors and the FAK inhibitors...

Investegate announcements from F. Hoffmann-La Roche Ltd, New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME

Roche will leverage PicnicHealth's real-world datasets for Alzheimer’s Disease, Alzheimer’s Disease-related dementia and myasthenia gravis.

Second-generation Brutons tyrosine kinase inhibitors are a great frontline option for most, if not all, patients with chronic lymphocytic leukemia (CLL), owing to their improved toxicity profiles.

Phase 3 data from the 2023 ARVO meeting showed treatment with the monoclonal antibody improved visual acuity in some patients.

The dynamics of the FAK inhibitor market is anticipated to change as companies across the globe are thoroughly working toward developing new FAK options with convenient RoA and better safety

Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or 'wet' age-related macular degeneration (nAMD) and diabetic macular edema

/PRNewswire/ -- Amber Semiconductor, Inc. (AmberSemi™), a leading technology developer of patented, innovative technologies for AC Direct digital management of...